Manchester Royal Eye Hospital

Running trials

• Recruiting

  A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

  NCT07144137· Complement Therapeutics· Source

• Recruiting

  Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial

  NCT05405868· Phase 3· University College, London· Source

• Recruiting

  Multicenter Glaucoma Study Investigating Standalone Canaloplasty

  NCT05786196· Nova Eye, Inc.· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Recruiting

  Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

  NCT04663750· Phase 3· King's College Hospital NHS Trust· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Glaucoma2 recruiting
• Macular degeneration2 recruiting

Closed trials

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

  NCT05797896· Complement Therapeutics· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Gyroscope Therapeutics Limited· Source

• Completed

  Stereotactic Radiotherapy for Wet AMD (STAR)

  NCT02243878· Phase 3· King's College Hospital NHS Trust· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Retinitis pigmentosa3 works · 0 trials